View Older Stories View More Recent Stories

Nov 29, 2023 08:30AM AI Innovation for automated Detection and Classification of osteoporotic Fractures of the Spine in CT Scans - ImageBiopsy Lab launches IB Lab FLAMINGO
Nov 14, 2023 07:00AM UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Nov 11, 2023 07:00AM Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
Nov 10, 2023 07:00AM UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
Nov 1, 2023 07:00AM UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Founda
Oct 31, 2023 07:00AM NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
Oct 18, 2023 07:00AM BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Oct 17, 2023 06:34PM UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
Oct 13, 2023 12:00PM UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
Oct 12, 2023 12:20PM Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
Oct 4, 2023 01:06PM UCB presents late-breaking posters at Child Neurology Society Meeting
Jul 21, 2023 07:00AM UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscl
Jun 27, 2023 07:00AM UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
Apr 20, 2023 07:00AM UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
Apr 17, 2023 07:14AM UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
Mar 18, 2023 02:10PM Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
Mar 16, 2023 07:00AM UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa
Mar 15, 2023 01:02PM Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease
Jan 18, 2023 07:00AM Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis
Jan 6, 2023 07:00AM UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review
Dec 13, 2022 04:07PM Praxis Precision Medicines (PRAX) and UCB Announce Epilepsy Research Collaboration
Dec 13, 2022 04:01PM Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
Dec 9, 2022 07:02AM UCB (UCBJY) announces positive phase 3 study of bimekizumab in hidradenitis suppurativa
Dec 9, 2022 07:00AM UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa
Dec 7, 2022 07:00AM The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis
Dec 1, 2022 07:00AM UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care
Nov 23, 2022 07:00AM Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)
Nov 14, 2022 07:00AM UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients
Nov 10, 2022 07:00AM Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Nov 8, 2022 12:12PM UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022
Sep 26, 2022 07:00AM UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS
Sep 22, 2022 07:00AM UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting
Sep 7, 2022 07:00AM New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis
Sep 1, 2022 10:00AM UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress
Aug 17, 2022 07:00AM UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters
May 23, 2022 12:16PM First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022
May 23, 2022 12:07PM UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022
May 10, 2022 07:00AM UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
May 2, 2022 01:30PM JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)
Apr 1, 2022 10:00AM UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting
Mar 28, 2022 01:00AM FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
Mar 26, 2022 10:30AM New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
Mar 7, 2022 12:00PM UCB Completes Acquisition of Zogenix, Inc. (ZGNX)
Mar 7, 2022 12:00PM UCB Completes Acquisition of Zogenix, Inc.
Feb 4, 2022 07:00AM UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results
Jan 21, 2022 08:50AM Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
Jan 19, 2022 01:00AM UCB to acquire Zogenix
Jan 18, 2022 09:09AM Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study
Dec 16, 2021 08:00AM Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial
Dec 10, 2021 07:00AM UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis
View More Recent Stories View Older Stories